18
May

08:00 AM EST

Medicinal Chemistry

Name: Medicinal Chemistry Strategy Meeting East Coast 2026 (Boston)
Start: 2026-01-01T08:00
End: 2026-05-20T18:00
Location: Crowne Plaza, London Docklands

Strategy Meeting East Coast USA 2026

Reinvigorating Productivity in Pharma Biotech Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms

Le Meridien Cambridge Boston

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Medicinal Chemistry Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Medicinal Chemistry professionals from across the East Coast, in Boston MA, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Meet Our Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Medicinal Chemistry strategy meeting.

Byron DeLaBarre

Executive Director, Head of Protein Science & Structural Biology PsiThera

Claire Elizabeth Smith

Partner SpringTide Ventures

Doug Johnson

Senior Director Biogen

George Naumov

Chief Operations Officer & Chief Business Officer RS Oncology

Hariprasad Vankayalapati

CSO Bioelexis Therapeutics

Hari is a co-founder, currently serving as Chief Scientific Officer of Biolexis Therapeutics, Inc., a clinical stage Biopharmaceutical company, discovering and developing novel, first-in-class small molecule targeted therapeutics for cancers, immune-mediated, auto-immune, inflammatory and metabolic diseases. Hari and his colleague Dr. David J. Bearss together developed the empirical-driven MolecuLernTM technology that has empirical/experimental data implemented in ML algorithms, accelerating drug discoveries, and successfully translating novel agents into clinical stage of development. Hari, after his decade of academic career, recently moved back to the pharmaceutical industry. Hari is the key in creating seven clinical agents: MP-470/Amuvatinib, SGI-1776, SGI-110/Guadecitabine, HCI-2577/SP-2577, HCI-2084/TP-0903, ARN-6039/BOS-172767/SLX-0528, ARN-3236/GRN-300 currently in various stages of clinical development. Hari received his Ph.D., and M. Pharm degrees in Medicinal Chemistry from the Institute of Chemical Technology (formerly UDCT) of the University of Mumbai and the University of Karnataka in India. His Postdoctoral training was in University of Sunderland in England and at the University of Arizona Cancer Center under Prof. Laurence H. Hurley. Hari is an author of ~100 plus publications, presentations, and he is an inventor of several issued/published US/WO patents.

Lijuan Jiang

Vice President, DMPK & Bioanalysis Enanta Pharmaceuticals

Jeff Norenberg

Co-Founder & Chief Executive Officer iSeek Biopharma

Markus Haeberlein

Executive Vice President, Discovery Science Parabilis Medicines

Markus is currently Executive Vice President, Discovery Science at Parabilis Medicines and holds three decades of experience in Drug Discovery and Early Development spanning many disease areas. Most recently, Markus served as Senior Vice President and Head of Research at Alkermes. During his tenure he helped build a strong research engine focused on exceptional molecular design of small molecules and biologics. An example is the discovery of ALKS 2680 for narcolepsy, a potent agonist for the difficult-to-drug Orexin 2 Receptor. Before Alkermes, Markus was Chief Scientific Officer at Proteostasis Therapeutics, a biotech focused on diseases caused by improper protein degradation, folding and trafficking. Prior to that, Markus spent 15 years at AstraZeneca and held roles of increasing scope and responsibility, including leading AstraZeneca’s Global Chemistry Network where he was responsible for the company’s global chemistry strategy and implementation. A key focus of his strategy was the Predictive Chemistry platform utilizing state-of-the-art computational chemistry methods to improve the design of drug molecules. Markus holds a M.Sc. in Physical Chemistry, Biochemistry, Organic Chemistry and a Ph.D. in Physical Chemistry/Computational Chemistry from the Royal Institute of Technology, Sweden

Matt Bursavich

Associate Vice President, Chemical Sciences Eli Lilly

Rocky Goldsmith

Chief Innovation Scientist / Co-Founder Congruence Therapeutics

Sean Jesinkey

Chief Business Officer Primera Therapeutics

Sridhar Narayan

Vice President Drug Discovery and Program Leadership Satellos Bioscience Inc.

Stephanie Oestreich

Managing Director Myeloma Investment Fund

OUR AGENDA

See Which Topics Are Discussed at the Strategy Meeting

09:00 – 10:00

Roundtable Tracks

AI/ML
AI-Driven Design for Challenging Modalities & “Hard” Targets (e.g. Kinases, Allosteric Sites, Undruggables, Protein Degraders)

-Matt Bursavich
Associate Vice President, Chemical Sciences
Eli Lilly

Design, Synthesis & Emerging Modalities
Small Molecule Design for Challenging PK/ADME Profiles

Chemical Biology, Targeted Protein Degradation And Undruggables
From Undruggable to Actionable: Chemical Biology Unlocks New Therapeutic Space

-Doug Johnson
Senior Director
Biogen

Hit Identification / Lead Optimization
Discovery in RNA & Oligonucleotide Therapeutics

-Sridhar Narayan
Vice President Drug Discovery and Program Leadership
Satellos Bioscience Inc.

Integrated Drug Discovery
Integrating Novel Modalities Into End to End Drug Discovery Pipelines

Strategic Partnerships In Drug Discovery
Partnering Science and Strategy: Translating Integrated Discovery Pipelines into Value for Investors, Collaborators, and Patients

-Jeff Norenberg
Co-Founder & Chief Executive Officer
iSeek Biopharma

Private Equity & Venture Capital
How Private Equity and Venture Capital Are Shaping the Future of Biotech Investment Strategies Across the Full Drug Discovery and Development Spectrum

-Stephanie Oestreich
Managing Director
Myeloma Investment Fund

11:10 – 12:10

Roundtable Tracks

AI/ML
The Autonomous Chemist: Large Chemical Models and Self-Driving Optimization Loops

SPONSOR

Design, Synthesis & Emerging Modalities
Transforming Medicinal Chemistry Through Connectivity: Integrated Platforms for Synthetic Design, Conjugation, and Targeted Protein Degradation

SPONSOR

Chemical Biology, Targeted Protein Degradation And Undruggables
The Next Generation of Degrader Architectures Reshaping Undruggable Targets in 2026 – Beyond PROTACs 2.0

SPONSOR

Hit Identification / Lead Optimization
Streamlining Chemistry, Biology, and Analytics: Integrated Platforms for Faster Hit to‑Lead and Lead-to‑Preclinical Transitions

SPONSOR

Integrated Drug Discovery
From Early‑Stage Discovery to Preclinical Development — Minimizing Failures through Integrated Workflows

REVVITY SIGNALS

Strategic Partnerships In Drug Discovery
Partnering Science and Strategy: Translating Integrated Discovery Pipelines into Value for Investors, Collaborators, and Patients

REVVITY SIGNALS

Private Equity & Venture Capital
The Role of Machine Learning and AI-Powered Data Platforms in Shaping Future Investment Decisions and Portfolio Strategy

SPONSOR

12:15 – 13:15

Roundtable Tracks

AI/ML
AI-Enabled Design for Complex Biology: CNS Targets, RNA Therapeutics, Multi-modal / Multitarget Drugs, Personalized Medicine

-Rocky Goldsmith
Chief Innovation Scientist / Co-Founder
Congruence Therapeutics

Design, Synthesis & Emerging Modalities
De-Risking Novel Modalities: Oligonucleotides, LNPs, RNA Therapeutics

Chemical Biology, Targeted Protein Degradation And Undruggables
Targeting the Undruggable at Scale Integrating Chemical Biology Deep Learning and Next-Gen Screening (Topic TBC)

-Markus Haeberlein
Executive Vice President, Discovery Science
Parabilis Medicines

Hit Identification / Lead Optimization
The New Frontier of Hit Identification: High-Dimension Screens, DNA-Encoded Libraries & Virtual Exploration

Integrated Drug Discovery
Automated Integrated Platforms Transforming Early Drug Discovery Timelines

Strategic Partnerships In Drug Discovery
Partnering to Shorten the Discovery and Development Timeline (Topic TBC)

-George Naumov
Chief Operations Officer & Chief Business Officer
RS Oncology

Private Equity & Venture Capital
Emerging Modalities, Emerging Markets: Identifying High-Impact Investment Opportunities in Cutting-Edge Biotech

-Claire Elizabeth Smith
Partner
SpringTide Ventures

14:40 – 15:10

Augmented Discovery: How Revvity Signals’ AI/ML Amplifies Scientific Discovery

David Gosalvez, Chief Strategy Officer, Revvity Signals

15:10 – 16:10

Roundtable Tracks

AI/ML
Converging Data, Science, and Automation: How Unified Digital Frameworks Accelerate Multi-Modal Drug Discovery

-Byron DeLaBarre
Executive Director, Head of Protein Science & Structural Biology
PsiThera

Design, Synthesis & Emerging Modalities
Process Chemistry Innovation: From Bench to GMP Manufacturing

Chemical Biology, Targeted Protein Degradation And Undruggables
Hit-to-Lead Strategies for PROTACs, Molecular Glues & Targeted Protein Degradation

Hit Identification / Lead Optimization
Structure Enabled Design Transforming Early Discovery and Fast Tracking Lead Optimization (Topic TBC)

-Lijuan Jiang
Vice President, DMPK & Bioanalysis
Enanta Pharmaceuticals

Integrated Drug Discovery
From Target to Tablet: End‑to‑End Small Molecule Drug Development via Integrated Discovery, DMPK, and Manufacture

Strategic Partnerships In Drug Discovery
Translational Partnerships: Bridging Early Discovery to Clinical Development

Private Equity & Venture Capital
Creating Long-Term Value Through Strategic Investments, Partnerships, and Portfolio Management in Small Biotech and Pharma Companies

See the full agenda and facilitator line-up Download the strategy meeting brochure for full details

DOWNLOAD THE BROCHURE

Reasons To Attend the Strategy Meeting

Discussions on the advancements in targeted protein degradation and pushing past its boundaries.

Leveraging Artificial Intelligence and Machine Learning in accelerating the development of new drugs

Discuss approaches to further understand the interactions of undruggable targets and different Protein Degraders such as PROTACs, Molecular Glues, etc

Focusing on advancing interrogative techniques to improve the Drug Delivery System/Discovery: Modified mRNA, Nanoparticle-Mediated siRNA, Antibody-Drug Conjugates, and more

Become an official strategy meeting partnerrnWhatever your business needs, we can help. Get in touch for partnering opportunities.

I’D LIKE TO PARTNER

Explore Highlight From The Past Events

Gain valuable insights, discover innovative solutions and connect with industry leaders through snapshots of our most successful gatherings.

Nov
2024

Nov
2023

May
2022

May
2021

Jun
2020

Event Gallery

Watch to hear what your colleagues had to say…

Hotel & Venue

Le Méridien Boston Cambridge

Le Méridien Cambridge-MIT’s elegant guest rooms and suites offer a place of luxurious sanctuary and unmatched comfort. Explore unique programs inspired by the brand’s European heritage. Born in a glamorous era of travel, Le Méridien believes everyone should explore the world in style.

Hotel Details Maps & Direction Parking

Here To Help

Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Boston

Medicinal Chemistry Strategy Meeting East Coast – Boston 2024

Medicinal Chemistry

Strategy Meeting East Coast USA 2026

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Le Meridien Cambridge Boston

Fresh Medicinal Chemistry Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Meet Our Facilitators

Byron DeLaBarre

Claire Elizabeth Smith

Doug Johnson

George Naumov

Hariprasad Vankayalapati

Lijuan Jiang

Jeff Norenberg

Markus Haeberlein

Matt Bursavich

Rocky Goldsmith

Sean Jesinkey

Sridhar Narayan

Stephanie Oestreich

OUR AGENDA

See Which Topics Are Discussed at the Strategy Meeting

Breakfast & Registration

Opening Keynote Presentation

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Refreshment Break

NETWORKING / 1-1 MEETINGS

NETWORKING / 1-1 MEETINGS

NETWORKING / 1-1 MEETINGS

Roundtable ( Solutions )

Roundtable Tracks

SPONSOR

SPONSOR

SPONSOR

SPONSOR

REVVITY SIGNALS

REVVITY SIGNALS

SPONSOR

Roundtable ( Pharma/Biotech )

Roundtable Tracks

NETWORKING LUNCH

Networking / 1-1 Meetings

AFTERNOON KEYNOTE PRESENTATION

Augmented Discovery: How Revvity Signals’ AI/ML Amplifies Scientific Discovery

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Afternoon Refreshment Break

Panel Discussion

Drinks & Canapes Reception

Reasons To Attend the Strategy Meeting

Our Past Sponsors

Lead Sponsor

Thought Leader

Co-Host Sponsor

Partnering Sponsors

Exhibitor

Media Partner

Explore Highlight From The Past Events

Event Gallery

Watch to hear what your colleagues had to say…

Hotel & Venue

Le Méridien Boston Cambridge

Here To Help

Select days you wish to attend You can add multiple days

Daily Delegate Rate includes:

VAT Excluded

Le Meridien Cambridge Boston